2 years in the life of COPD patients: Evolution of GOLD 2011 classification in the ’real-life’ DACCORD study

Roland Buhl (Mainz, Germany), Roland Buhl, Carl-Peter Criée, Peter Kardos, Claus Vogelmeier, Claudia Mailänder, Nadine Lossi, Heinrich Worth

Source: International Congress 2016 – Comorbidities and exacerbations in COPD
Session: Comorbidities and exacerbations in COPD
Session type: Thematic Poster
Number: 1124
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Roland Buhl (Mainz, Germany), Roland Buhl, Carl-Peter Criée, Peter Kardos, Claus Vogelmeier, Claudia Mailänder, Nadine Lossi, Heinrich Worth. 2 years in the life of COPD patients: Evolution of GOLD 2011 classification in the ’real-life’ DACCORD study. Eur Respir J 2016; 48: Suppl. 60, 1124

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Three year follow-up of distribution and stability of patients with COPD according GOLD 2014
Source: International Congress 2015 – Clinical assessment in asthma and COPD
Year: 2015


COPD: GOLD 2011 and implications for clinical practice
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013

COPD comorbidities and risk assessment according to GOLD 2011 revision
Source: Annual Congress 2013 –Monitoring respiratory diseases: role of comorbidities and lung involvement
Year: 2013


Evaluation of the GOLD 2011 severity criteria across the COPD spectrum
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013

Outcomes in patients with COPD during a 3 year follow-up
Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD
Year: 2015


Survival in three years of COPD patients according to GOLD 2003 and GOLD 2014
Source: International Congress 2015 – Latest insights into the management of chronic respiratory diseases
Year: 2015

New GOLD recommendations in a seven years follow up - changes in symptoms and risk categories
Source: Annual Congress 2013 –Quality of diagnosis and assessment in primary care
Year: 2013

Analysis of the frequency of COPD exacerbations in the ’real-life’ DACCORD study over a 2 year period
Source: International Congress 2016 – Comorbidities and exacerbations in COPD
Year: 2016


GOLD and phenotypes: The new Czech COPD guidelines
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015


High risk COPD patients cost less if treated according to GOLD 2011 recommendations
Source: Annual Congress 2013 –COPD diagnosis
Year: 2013


GOLD 2017 versus GOLD 2011 - comparison of the risk of exacerbations and mortality in COPD patients
Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD?
Year: 2018




Symptomatic assessment in COPD GOLD 2011 classification - mMRC/CAT agreement
Source: International Congress 2016 – Screening, diagnosis, assessment, and treatment of COPD in primary care
Year: 2016

The BODE index predicts mortality better than 2007 GOLD and GOLD ABCD
Source: International Congress 2014 – COPD exacerbations
Year: 2014


Heterogeneity of group D in the new GOLD classification of COPD
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016


Comparison of 2011 and 2007 GOLD guidelines for predicting mortality and hospitalization
Source: Annual Congress 2013 –Investigating COPD in longitudinal studies
Year: 2013


LATE-BREAKING ABSTRACT: Stratification of patients with COPD by frequence of exacerbations is an essential step for what to treat in COPD. - A survey in a real life COPD population
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013


Evolution of COPD phenotypes in time - Czech multicentre research database of severe COPD
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016


Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016

GOLD BCD or 234 classifications: Which one better reflects COPD patients' functionality?
Source: International Congress 2014 – Physical activity, exercise and physiotherapy in patients with COPD
Year: 2014


Phenotypical heterogeneity of severe COPD subjects: Baseline results from the Czech multicentre research database of COPD
Source: International Congress 2015 – Monitoring and phenotyping COPD
Year: 2015